The THC Testkit was developed and produced by Farmako in-house as a tool for pharmacists to detect THC and identify medical cannabis flowers and extracts easily, quickly and at low cost
AgraFlora Organics International Inc (CSE: AGRA) (FRA:PU31) (OTCPINK:AGFAF) announced that its German pharmaceutical wholesale subsidiary, Farmako GmbH, has begun supplying its proprietary THC Testkits to Stadapharm GmbH.
The THC Testkit was developed and produced by Farmako in-house as a tool for pharmacists to detect THC and identify medical cannabis flowers and extracts easily, quickly and at low cost, the company said.
Stadapharm, which is responsible for the specialty pharmaceuticals business within the German STADA Group, is expected to enter the medical cannabis market in the second quarter of 2021. The company plans to launch its own THC cannabis flower products and extracts and will also offer the Farmako THC Testkits, the company said.
READ: AgraFlora Organics CEO says recent asset sales give ‘us the financial flexibility’ to enter lucrative markets
“Katrin and everyone at Farmako continue to demonstrate their ingenuity and passion for the cannabis industry in Germany,” AgraFlora CEO Elise Coppens said in a statement. “I am very proud of the team and commend their efforts to develop the THC Testkit in-house, obtain patent protection, bring it to market and secure the supply agreement with Stadapharm.”
Farmako has been supplying THC Testkits to pharmacies since December 2020, the company said. The kits facilitate identity testing of cannabis in only five minutes, without the need for further auxiliary devices or expensive reference substances, the company said – thus offering a better alternative to the time-consuming and costly thin layer chromatography method of identity testing pharmaceutical ingredients or medicines containing THC.
“Discussion in the German cannabis market often circles around the high barriers for patients, suppliers, doctors and pharmacists,” Farmako CEO Katrin Eckmans said. “Therefore, we as Farmako want to facilitate easier access to cannabinoid therapy for patients with a high burden of suffering via fair prices, reliable supply and efficient service for healthcare professionals. For us, cooperation is an important element of competition, only in this way can we develop the market for the benefit of patients. Therefore, we are very happy about this partnership with Stadapharm, a highly renowned pharma corporation,”
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel